News

Velocity Aggressively Expands MASH/MASLD Capabilities with Latest Site Acquisitions

Velocity Expands MASH/MASLD Capabilities With New Sites in Seattle, WA, and Waco, TX

Velocity Clinical Research, the leading multi-specialty clinical sites business, announced it has acquired Impact Research Institute (Waco, TX) and the clinical trials unit of Liver Institute Northwest (Seattle, WA), aggressively expanding its capabilities in liver disease research, including MASH (metabolic dysfunction-associated steatohepatitis) and MASLD (metabolic dysfunction-associated steatotic liver disease). According to the NASH education program, … Read more

Julio Rosenstock, MD, FACE, Presents Promising Data on Oral Semaglutide’s Effect on HbA1c for Adults with Prediabetes

Julio Rosenstock, MD, FACE, presents promising data on oral semaglutide’s effect on HbA1c for adults with prediabetes

Julio Rosenstock, MD, FACE, Principal Investigator at Velocity and the leader of the Diabetes and Obesity CARE Council, unveiled data suggesting a potential breakthrough for adults with prediabetes. When administered oral semaglutide, trial participants achieved normoglycemia at 68 weeks. Dr. Rosenstock commented, “Those people who participated in the OASIS 1 trial with prediabetes who received … Read more

Velocity Eczema Trials Enhance Patient Quality of Life

Shiva Muthiah, Director of UK Operations for Velocity, smiles as she recalls the triumph of a teenage patient battling a painful eczema skin condition. “He used to wear long sleeves and other clothing designed to hide the marks on his skin, but almost immediately after beginning treatment in our clinical trial, the improvement was dramatic … Read more

Velocity Launches Cardiology Council to Accelerate Research Excellence (CARE)

Velocity is proud to unveil another groundbreaking initiative: the Cardiology Council to Accelerate Research Excellence (CARE). Headed by William Cromwell, MD, FAHA, FNLA and Steven Martin, MD, FACC, the Cardiology CARE Council will support strategic partnerships with Sponsors and CROs, backed by Velocity’s extensive track record of success in cardiology clinical trials. Heart disease remains … Read more

Velocity Wins the 2023 SCRS Excellence in Patient Centricity Award

Velocity has won the 2023 SCRS Excellence in Patient Centricity Award. The award was presented to the Velocity team at the 2023 Global Site Solutions Summit in Hollywood, FL. This award recognizes an organization that has “proven its commitment to effective patient engagement by understanding clinical research from the patient perspective. Through the consideration of … Read more

Velocity Opens Three UK Greenfield Clinical Research Sites

Velocity Clinical Research, the leading multi-specialty clinical sites business, announced it is opening greenfield clinical research sites in Bristol, Leicester, and Romford, demonstrating the company’s commitment to the U.K. market.  The sites launch at a time when clinical trial activity in the U.K. has fallen in recent years. The number of patients enrolled in commercial … Read more

Six Velocity Principal Investigators Co-Author Article Published in Nature Medicine

A quote from the article.

Six Velocity Principal Investigators coauthored an article recently published in Nature Medicine. The article covers the results of a Phase 2/3 trial of the Omicron BA.4/BA.5-containing bivalent mRNA-1273.222 vaccine with the ancestral Wuhan-Hu-1 mRNA-1273 as booster doses. Beyond yielding promising results, the trial has set the groundwork for swiftly addressing circulating variants as SARS-CoV-2 continues … Read more

‘New Era’ for Alzheimer’s Treatments Spur Researcher Optimism

‘New Era’ for Alzheimer’s Treatments Spur Researcher Optimism

After battling on the frontline for many years against an aggressive and elusive opponent, Michael Hemphill, MD and the Velocity team in Savannah, GA, believe we’ve entered an exciting “new era” in the fight against Alzheimer’s disease and dementia. Velocity conducts clinical trials related to disorders of the nervous system in Savannah as an embedded research … Read more

Velocity Syracuse Team Advances Important Alzheimer’s Trials 

Velocity Syracuse Team Advances Important Alzheimer’s Trials

Alzheimer’s is currently ranked as the seventh leading cause of death in the United States and is the most common cause of dementia among older adults.  Alzheimer’s disease, a cruel and pernicious affliction, is a brain disorder that slowly destroys memory, thinking skills, and eventually, the ability to carry out even the most simple and … Read more

Velocity Launches Vaccine Council to Accelerate Research Excellence (CARE)

Velocity Launches Vaccine Council to Accelerate Research Excellence (CARE)

Velocity has introduced the Vaccine Council to Accelerate Research Excellence (CARE). This council will bring world-class operational, patient recruitment, and trial conduct oversight to all Velocity sites conducting vaccine studies in the U.S. and Europe. Led by some of the world’s top vaccine Principal Investigators, including Brandon Essink, MD, CPI, the Vaccine CARE Council will … Read more